Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Function Improvement Switching from Lamivudine to Telbivudine in Kidney Transplant Patients
NCT02894554Phase 4Terminated
- Sponsor
- National Taiwan University Hospital
- Start
- Jul 2014
- Primary completion
- Oct 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 4, randomised, open-label trial of telbivudine in Chronic Hepatitis B (CHB) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Estimated Glomerular Filtration Rate at 48 weeks. Started Jul 2014; status: terminated.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02894554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02894554.